Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Assessment of the long-term efficacy and safety of adjunctive perampanel in tonic-clonic seizures: Analysis of four open-label extension studies

I. Rektor, GL. Krauss, Y. Inoue, S. Kaneko, B. Williams, A. Patten, M. Malhotra, A. Laurenza, RT. Wechsler,

. 2020 ; 61 (7) : 1491-1502. [pub] 20200709

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze II, klinické zkoušky, fáze III, časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20028047

Grantová podpora
Eisai Inc. - International

OBJECTIVE: This post hoc analysis evaluated long-term efficacy and safety in patients with focal to bilateral tonic-clonic seizures (FBTCS) or generalized tonic-clonic seizures (GTCS) who entered open-label extension (OLEx) studies to receive long-term adjunctive perampanel. METHODS: Patients aged 12 years and older who completed phase II or III randomized, double-blind, placebo-controlled studies could enter an OLEx study, each comprising a blinded conversion period followed by an open-label maintenance period (32-424 weeks; maximum perampanel dose = 12 mg/d). Exposure, seizure outcomes, and treatment-emergent adverse events (TEAEs) were analyzed. RESULTS: Baseline characteristics were generally balanced between patients with FBTCS (n = 720) and GTCS (n = 138). Mean (standard deviation) cumulative duration of perampanel exposure was 102.3 (70.3) weeks (FBTCS) and 83.9 (38.4) weeks (GTCS). Retention rates were 50.0% for up to 4 years (FBTCS) and 49.2% for up to 2 years (GTCS). Across OLEx treatment durations, median reductions in seizure frequency per 28 days were 66.7% (FBTCS) and 80.6% (GTCS). Fifty percent and 75% responder and seizure-freedom rates were 59.5%, 45.3%, and 18.4%, respectively (FBTCS), and 72.5%, 51.5%, and 16.7%, respectively (GTCS). Efficacy was sustained for up to 4 years (FBTCS) and up to 3 years (GTCS), even when accounting for early dropouts. TEAE incidence was highest during Year 1 (FBTCS, 85.3%; GTCS, 86.2%); most common were dizziness and somnolence. During Year 1, serious TEAEs were reported in 81 (11.3%; FBTCS) and 10 (7.2%; GTCS) patients. TEAEs were consistent with the known safety profile of perampanel; no new safety signals were identified with long-term treatment. SIGNIFICANCE: This post hoc analysis suggests long-term (up to 4 years) adjunctive perampanel (up to 12 mg/d) is efficacious and well tolerated in patients (aged 12 years and older) with FBTCS or GTCS.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20028047
003      
CZ-PrNML
005      
20210114152854.0
007      
ta
008      
210105s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1111/epi.16573 $2 doi
035    __
$a (PubMed)32645213
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Rektor, Ivan $u Brno Epilepsy Center and Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic.
245    10
$a Assessment of the long-term efficacy and safety of adjunctive perampanel in tonic-clonic seizures: Analysis of four open-label extension studies / $c I. Rektor, GL. Krauss, Y. Inoue, S. Kaneko, B. Williams, A. Patten, M. Malhotra, A. Laurenza, RT. Wechsler,
520    9_
$a OBJECTIVE: This post hoc analysis evaluated long-term efficacy and safety in patients with focal to bilateral tonic-clonic seizures (FBTCS) or generalized tonic-clonic seizures (GTCS) who entered open-label extension (OLEx) studies to receive long-term adjunctive perampanel. METHODS: Patients aged 12 years and older who completed phase II or III randomized, double-blind, placebo-controlled studies could enter an OLEx study, each comprising a blinded conversion period followed by an open-label maintenance period (32-424 weeks; maximum perampanel dose = 12 mg/d). Exposure, seizure outcomes, and treatment-emergent adverse events (TEAEs) were analyzed. RESULTS: Baseline characteristics were generally balanced between patients with FBTCS (n = 720) and GTCS (n = 138). Mean (standard deviation) cumulative duration of perampanel exposure was 102.3 (70.3) weeks (FBTCS) and 83.9 (38.4) weeks (GTCS). Retention rates were 50.0% for up to 4 years (FBTCS) and 49.2% for up to 2 years (GTCS). Across OLEx treatment durations, median reductions in seizure frequency per 28 days were 66.7% (FBTCS) and 80.6% (GTCS). Fifty percent and 75% responder and seizure-freedom rates were 59.5%, 45.3%, and 18.4%, respectively (FBTCS), and 72.5%, 51.5%, and 16.7%, respectively (GTCS). Efficacy was sustained for up to 4 years (FBTCS) and up to 3 years (GTCS), even when accounting for early dropouts. TEAE incidence was highest during Year 1 (FBTCS, 85.3%; GTCS, 86.2%); most common were dizziness and somnolence. During Year 1, serious TEAEs were reported in 81 (11.3%; FBTCS) and 10 (7.2%; GTCS) patients. TEAEs were consistent with the known safety profile of perampanel; no new safety signals were identified with long-term treatment. SIGNIFICANCE: This post hoc analysis suggests long-term (up to 4 years) adjunctive perampanel (up to 12 mg/d) is efficacious and well tolerated in patients (aged 12 years and older) with FBTCS or GTCS.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a antikonvulziva $x aplikace a dávkování $x škodlivé účinky $7 D000927
650    _2
$a závrať $x chemicky indukované $7 D004244
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a kombinovaná farmakoterapie $7 D004359
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a pyridony $x aplikace a dávkování $x škodlivé účinky $7 D011728
650    _2
$a záchvaty $x diagnóza $x farmakoterapie $x epidemiologie $7 D012640
650    _2
$a somnolence $7 D000077260
650    _2
$a časové faktory $7 D013997
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Krauss, Gregory L $u Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
700    1_
$a Inoue, Yushi $u National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan.
700    1_
$a Kaneko, Sunao $u North Tohoku Epilepsy Center, Minato Hospital, Hachinohe, Japan.
700    1_
$a Williams, Betsy $u Formerly: Eisai Inc., Woodcliff Lake, New Jersey, USA.
700    1_
$a Patten, Anna $u Eisai Ltd., Hatfield, UK.
700    1_
$a Malhotra, Manoj $u Eisai Inc., Woodcliff Lake, New Jersey, USA.
700    1_
$a Laurenza, Antonio $u Formerly: Eisai Inc., Woodcliff Lake, New Jersey, USA.
700    1_
$a Wechsler, Robert T $u Idaho Comprehensive Epilepsy Center, Boise, Idaho, USA.
773    0_
$w MED00001567 $t Epilepsia $x 1528-1167 $g Roč. 61, č. 7 (2020), s. 1491-1502
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32645213 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114152851 $b ABA008
999    __
$a ok $b bmc $g 1608382 $s 1119227
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 61 $c 7 $d 1491-1502 $e 20200709 $i 1528-1167 $m Epilepsia $n Epilepsia $x MED00001567
GRA    __
$p Eisai Inc. $2 International
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Možnosti archivace